Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients.

Abstract

BACKGROUND:

Antibiotics are frequently used to treat hidradenitis suppurativa (HS); however, few data on their efficacy are available.

OBJECTIVE:

To evaluate the efficacy of a combination of systemic clindamycin (300 mg twice daily) and rifampicin (600 mg daily) in the treatment of patients with severe HS.

METHODS:

Patients (n = 116) who received this combination were studied retrospectively. The main outcome measure was the severity of the disease, assessed by the Sartorius score, before and after 10 weeks of treatment.

RESULTS:

The Sartorius score dramatically improved at the end of treatment (median = 29, interquartile range = 14.5, vs. median = 14.5, interquartile range = 11; p < 0.001), as did other parameters of severity as well as the quality of life score. Eight patients (6.9%) stopped the treatment because of side effects.

CONCLUSION:

The combination of clindamycin and rifampicin is effective in the treatment of severe HS.

• Authors: G Gener, F Canoui-Poitrine, J E Revuz, O Faye, F Poli, G Gabison, F Pouget, C Viallette, P Wolkenstein, S Bastuji-Garin
• Journal: Dermatology (Basel, Switzerland) (Dermatology) Vol. 219 Issue 2 Pg. 148-54 ( 2009) ISSN: 1421-9832 [Electronic] Switzerland
• PMID: 19590173 (Publication Type: Journal Article)
• Copyright: Copyright 2009 S. Karger AG, Basel.

Chemical References

• Clindamycin
• Rifampin

Topics

• Administration, Oral
• Clindamycin (administration & dosage)
• Cohort Studies
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Drug Therapy, Combination
• Female
• Follow-Up Studies
• Hidradenitis Suppurativa (diagnosis, drug therapy)
• Humans
• Male
• Patient Satisfaction (statistics & numerical data)
• Quality of Life
• Retrospective Studies
• Rifampin (administration & dosage)
• Severity of Illness Index
• Treatment Outcome